A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days-Reference-Cited by-同舟云学术

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

Published:2006-12-19 Issue:1 Volume:96 Page:29-37
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Benson C,White J,Bono J De,O'Donnell A,Raynaud F,Cruickshank C,McGrath H,Walton M,Workman P,Kaye S,Cassidy J,Gianella-Borradori A,Judson I,Twelves C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6603509.pdf

Reference29 articles.

1. Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A, Lane DP, Hubank M, Powell JE, Wei W, Taylor AMR, Moss PAH, Tatjana Stankovic T (2005) A novel Cdk inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 105: 4484–4491

2. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, Koken M, Coburn SP, Tang L, Jiang T, Liang DC, Galons H, Dierick JF, Pinna LA, Meggio F, Tozke F, Schachtele C, Lerman AS, Carno A, Wan Y, Gray N, Meijer L (2005) Roscovitine targets: protein kinase and pyridoxal kinase. J Biol Chem 280: 31208–31219

3. Benson B, Kaye S, Workman P, Garrett M, Walton M, de Bono J (2005) Clinical anticancer drug development: targeting the cyclin dependent kinase. Br J Cancer 92: 7–12

4. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243: 518–526

5. De la Motte S, Gianella-Borradori A (2004) Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 42: 232–239

Cited by 234 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia;Biomacromolecules;2024-09-05

2. Ibulocydine Inhibits Migration and Invasion of TNBC Cells via MMP-9 Regulation;International Journal of Molecular Sciences;2024-06-01

3. Limited high-throughput screening compatibility of the phenuivirus cap-binding domain;Scientific Reports;2023-12-20

4. New spiro-indeno[1,2- b ]quinoxalines clubbed with benzimidazole scaffold as CDK2 inhibitors for halting non-small cell lung cancer; stereoselective synthesis, molecular dynamics and structural insights;Journal of Enzyme Inhibition and Medicinal Chemistry;2023-11-23

5. Inhibition of GCN2 Reveals Synergy with Cell-Cycle Regulation and Proteostasis;Metabolites;2023-10-09